Sierra J, Mareque M, Montesinos P, Guinea JM, Font P, Oyaguez I, Brockbank J, Candini D, Llinares J, Soto J, de la Fuente A. Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy for first-line treatment of patients with CD33-positive acute myeloid leukemia in Spain. Poster presented at the 2020 Virtual European Hematology Association; June 2020.
Mokgokong R, Mamolo C, Cappelleri J, Knight C, Brockbank J, Cawson M, Dombre H, Castaigne S. Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy (daunorubicin and cytarabine) for first-line treatment of acute myeloid leukaemia. Poster presented at the 2019 British Society for Haematology Meeting; April 1, 2019. Glasgow, Scotland.
Walter R, Mamolo C, Welch V, Brockbank J, Cawson M, Knight C, Wilson M. Budget-impact analysis for gemtuzumab ozogamicin in CD33+ acute Myeloid Leukemia. Poster presented at the XXXVII World Congress International Society of Hematology (ISH); September 14, 2018. Vancouver, Canada.
Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or total knee replacement. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Rosseli D, Rueda J, Wolowacz SE, Brockbank JA, Abeysinghe SS. Cost-effectiveness of dabigatran compared with warfarin, apixaban, rivaroxaban and low molecular weight heparins for the treatment and secondary prevention of venous thromboembolism in Colombia. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.